Tag

Cell Therapies

Fireside Chat: Building the Future from a Distinguished Tenure in CMC
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Fireside Chat: Building the Future from a Distinguished Tenure in CMC

Introducing Prime Medicine and its vision for the future of medicine How are we thinking about the inclusion of novel types of automation into molecular medicine workflows? Examining how we view Talent in the emergent technology space, and how do we best deploy remote and hybrid work? Historically, pharmaceutical manufacturing leaders were predominantly men; however, many important CMC leadership positions are now held by women. Why is this the case, and how do we sustain this pattern? What are the most significant learnings from having achieved success in licensing autologous cell therapies? — Ann Lee Chief Technical Officer Prime Medicine…

Continue reading
Industrialization of CAR-T Therapies – Autologous vs Allogeneic: Common and Uncommon Hurdles
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Industrialization of CAR-T Therapies – Autologous vs Allogeneic: Common and Uncommon Hurdles

Industry evolution at a glance Donor Variability, the greatest source of variability for cell therapies. Thoughts on characterizing and accommodating this variability Process considerations for Autologous CAR and the importance of a good data ecosystem to provide insight and understanding to this highly complex therapeutic modality Brief introduction to Kyverna — Karen Walker Chief Technology Officer Kyverna Therapeutics Karen Walker, Chief Technology Officer, Kyverna Therapeutics.  Karen brings >30 years’ experience in the biotech industry, holding positions in Technical Development, Regulatory Affairs and Quality. She has worked in a number of companies including Roche/Genentech, Seattle Genetics, Novartis, Amgen, Bayer, and several…

Continue reading
Manufacturing Autologus Ex Vivo Genetically Modified Cell Therapies have Challenges, but the Future is Bright
LIFE SCIENCES, LIFE SCIENCES, VIDEO

Manufacturing Autologus Ex Vivo Genetically Modified Cell Therapies have Challenges, but the Future is Bright

Review the supply chain Examine the contributors of costs Solution for industrial scale viral vector manufacturing Cell processing and viral transduction hubs Rapid analytics for product testing Brighter future for patients with fitter cell therapies — Joseph Tarnowski SVP, Cell & Gene Therapy, R&D Medicinal Science and Technology GSK Prior to his current role in CGT, Joe was the Senior Vice President of Biopharm CMC R&D. Before joining GSK in June, 2010, Joe was the Senior Vice President, Biologics Manufacturing and Process Development in the Technical Operations division of Bristol-Myers Squibb Co. in New Brunswick, NJ. Joe was responsible for…

Continue reading